If you have been reading about selectivity and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-12-21. Where a claim depends on a specific study, the study is described rather than over-claimed.
Ipamorelin is a synthetic pentapeptide classified as a growth hormone secretagogue. Its sequence, Aib-His-D-2-Nal-D-Phe-Lys-NH2, combines three non-proteinogenic residues with a C-terminal amide. The N-terminal aminoisobutyric acid unit and the two aromatic D-amino acids distinguish it from peptides assembled only from standard L-amino acids. Its formula is C38H49N9O5, corresponding to an average mass near 711.9 Da. At neutral pH the molecule carries a net positive charge, a property that shapes its behaviour in chromatographic and electrophoretic systems.
The compound was developed at Novo Nordisk during the 1990s as part of a programme seeking secretagogues with improved selectivity. It was described in the peer-reviewed literature in 1998 alongside related pentapeptides from the same series. Investigators advanced it because it raised growth hormone output in animal models while leaving other pituitary hormones comparatively unaffected. The development code NNC 26-0161 appears in earlier reports, and ipamorelin later became the common designation in published work.
Selectivity is the property most often attached to this peptide. Published animal and early human studies record increases in growth hormone release after administration, with adrenocorticotropic hormone and cortisol responses remaining small by comparison. Effects on appetite-related pathways also appear weaker than those reported for several earlier secretagogues. Reviews that compare members of the growth hormone secretagogue family cite these findings frequently, though the receptor-level explanation for the selectivity continues to be debated rather than settled.
Common solvents for laboratory work include water, buffered saline, and dimethyl sulfoxide. Once dissolved, the peptide is exposed to hydrolysis and oxidation, and alkaline conditions accelerate breakdown. Low-binding plasticware and the addition of a carrier protein reduce losses to container surfaces, which can otherwise be substantial at low concentrations. Solutions are typically kept cold and used within days. Investigators working with the compound generally prepare fresh working dilutions rather than storing dilute stocks, and they avoid repeated warming of the same vial.
Reversed-phase high-performance liquid chromatography is the standard method for purity assessment, most often on a C18 column with a water and acetonitrile gradient and trifluoroacetic acid or formic acid as an ion-pairing agent. Mass spectrometry by electrospray or matrix-assisted laser desorption confirms the expected mass and reveals truncated or modified sequences. Amino acid analysis and sequencing provide orthogonal structural evidence. Typical impurities include deletion sequences, oxidized products, and dimeric species. Detection wavelength, usually 214 or 220 nanometers, should be reported because response factors differ between peptides.
Purity is normally reported as a percentage of total peak area, a figure that does not account for water content, residual solvents, or counterions. Trifluoroacetate and acetate are the most frequent counterions in lyophilized peptides, and they shift the true peptide content away from the mass of the powder. A separate quantitative assay is therefore needed to state content accurately. Certificates of analysis often omit these details, which makes batch-to-batch comparison difficult and limits conclusions drawn when results from different suppliers are compared.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Pentapeptide with C-terminal amide |
| Average mass | Approximately 711.9 Da | Value derived from the formula |
| Appearance | White to off-white powder | Typically supplied as a lyophilised solid |
| Solubility | Soluble in water and aqueous acetonitrile | Dissolution aided by acidic diluents |
| Common synonyms | Ipamorelin; NNC 26-0161 | Code name used in early reports |
Lyophilized material is generally stored cold and dry, with desiccant, and protected from light. In solution the peptide is more vulnerable: the histidine side chain can oxidize, and repeated freeze-thaw cycles promote aggregation and loss of material to container surfaces. A mildly acidic aqueous buffer is often used for short-term handling because it limits several degradation routes. Accurate prediction of long-term stability under a given set of conditions is difficult, and published stability data remain sparse.
Published discussion of this compound is uneven. Some references describe it as a tool for probing growth hormone regulation, while others focus on analytical characterization or on comparisons with related secretagogues. Statements about selectivity, half-life and potency often trace back to a small number of original reports that later authors cite secondhand. Readers evaluating a claim should therefore check whether a figure reflects a direct measurement or a repeated citation, and whether the underlying study was conducted in animals, in isolated cells or in human volunteers.
Most published work on ipamorelin comes from rodent studies and small early-phase human trials. Subcutaneous and intravenous routes have been used, while oral delivery is limited by poor absorption and rapid breakdown in the gut. The reported plasma half-life is short, on the order of two hours, and varies with species and assay method. Whether chronic use produces meaningful clinical benefit remains unresolved, and long-term safety data in humans are sparse. No major regulatory agency has approved the compound as a therapeutic drug.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues that resist enzymatic breakdown. Researchers at Novo Nordisk described the compound in the 1990s while searching for agents that release growth hormone with fewer side effects than earlier secretagogues. The molecule acts as an agonist at the ghrelin receptor, also called GHS-R1a, which is expressed in the pituitary and in several peripheral tissues.
Selectivity distinguishes ipamorelin from first-generation secretagogues such as GHRP-6. At doses that reliably raise growth hormone, it shows little stimulation of adrenocorticotropic hormone or cortisol release in animal models, and it does not markedly raise prolactin or appetite. Binding at GHS-R1a on pituitary somatotrophs triggers calcium influx and pulsatile growth hormone secretion. Because the compound mimics the natural ghrelin signal, the release pattern tends to follow the body's own rhythm rather than producing a sustained elevation.
Now EC 1.14.14.46, pimeloyl-[acyl-carrier protein] synthase EC 1.14.15.13: pulcherriminic acid synthase EC 1.14.15.14: methyl-branched lipid ω-hydroxylase EC 1.14.15.15: cholestanetriol 26-monooxygenase EC 1.14.15.16: vitamin D3 24-hydroxylase EC 1.14.15.17: pheophorbide a oxygenase EC 1.14.15.18: calcidiol 1-monooxygenase EC 1.14.15.19: C-19 steroid 1α-hydroxylase EC 1.14.15.20: heme oxygenase (biliverdin-producing, ferredoxin) EC 1.14.15.21: zeaxanthin epoxidase EC 1.14.15.22: vitamin D 1,25-hydroxylase EC 1.14.15.23: chloroacetanilide N-alkylformylase EC 1.14.15.24: β-carotene 3-hydroxylase EC 1.14.15.25: p-cymene methyl-monooxygenase EC 1.14.15.26: toluene methyl-monooxygenase EC 1.14.15.27: β-dihydromenaquinone-9 ω-hydroxylase EC 1.14.15.28: cholest-4-en-3-one 26-monooxygenase [(25R)-3-oxocholest-4-en-26-oate forming] EC 1.14.15.29: cholest-4-en-3-one 26-monooxygenase [(25S)-3-oxocholest-4-en-26-oate forming] EC 1.14.15.30: 3-ketosteroid 9α-monooxygenase EC 1.14.15.31: 2-hydroxy-5-methyl-1-naphthoate 7-hydroxylase EC 1.14.15.32: pentalenene oxygenase EC 1.14.15.33: pikromycin synthase EC 1.14.15.34: 20-oxo-5-O-mycaminosyltylactone 23-monooxygenase EC 1.14.15.35: 6-deoxyerythronolide B hydroxylase EC 1.14.15.36: sterol 14α-demethylase (ferredoxin) EC 1.14.15.37: luteothin monooxygenase EC 1.14.15.38: N,N-dimethyl phenylurea N-demethylase EC 1.14.15.39: epi-isozizaene 5-monooxygenase
=== Location and Position === The apical foramen is the principal opening at a tooth's root terminus, serving as the conduit between the root canal system and the periapical tissues. Its location is variable, as it frequently deviates from the anatomical apex—the root's geometric tip. Studies indicate that in a majority of cases, the foramen is positioned laterally, most commonly on the distal aspect. The average deviation is typically less than 1 millimeter, though greater distances are observed in specific teeth such as mandibular canines and molars. The foramen's morphology is often oval but can be circular or irregular. Its precise location and shape can be influenced by ethnic background, age, and physiological changes. In clinical endodontics, accurate identification of the apical foramen, rather than reliance on the radiographic apex alone, is essential for determining the correct working length and ensuring treatment success.
On the other hand, all neuronal voltage-activated sodium channels inactivate within several milliseconds during strong depolarization, thus making following depolarization impossible until a substantial fraction of sodium channels have returned to their closed state. Although it limits the frequency of firing, the absolute refractory period ensures that the action potential moves in only one direction along an axon. The currents flowing in due to an action potential spread out in both directions along the axon. However, only the unfired part of the axon can respond with an action potential; the part that has just fired is unresponsive until the action potential is safely out of range and cannot restimulate that part. In the usual orthodromic conduction, the action potential propagates from the axon hillock towards the synaptic knobs (the axonal termini); propagation in the opposite direction—known as antidromic conduction—is very rare. However, if a laboratory axon is stimulated in its middle, both halves of the axon are "fresh", i.e., unfired; then two action potentials will be generated, one traveling towards the axon hillock and the other traveling towards the synaptic knobs.
Sources: en.wikipedia.org
=== C-Linked glycans === Of the three linkages the least common and least understood are C-linked glycans. The C-linkage refers to the covalent attachment of mannose to a tryptophan residue. An example of a C-linked glycan is α-mannosyl tryptophan.
SSRIs can also induce apoptosis, programmed cell death, in T-cells. The full mechanism of action for the anti-inflammatory effects of SSRIs is not fully known. However, there is evidence for various pathways to have a hand in the mechanism. One such possible mechanism is the increased levels of cyclic adenosine monophosphate (cAMP) as a result of interference with activation of protein kinase A (PKA), a cAMP-dependent protein. Other possible pathways include interference with calcium ion channels, or inducing cell death pathways like MAPK and Notch signaling pathway. The anti-inflammatory effects of SSRIs have prompted studies of the efficacy of SSRIs in the treatment of autoimmune diseases such as multiple sclerosis, RA, inflammatory bowel diseases, and septic shock. These studies have been performed in animal models but have shown consistent immune regulatory effects. Fluoxetine, an SSRI, has also shown efficacy in animal models of graft vs. host disease. SSRIs have also been used successfully as pain relievers in patients undergoing oncology treatment. The effectiveness of this has been hypothesized to be at least in part due to the anti-inflammatory effects of SSRIs.
== Further reading == Juego, Bonn (2017). "The Philippines 2017: Duterte-led authoritarian populism and its liberal-democratic roots" (PDF). Asia Maior; the Journal of the Italian Think Tank on Asia Founded by Giorgio Borsa in 1989. XXVIII. Viella s.r.l. & Associazione Asia Maior: 129–163. ISSN 2385-2526. Archived from the original (PDF) on December 1, 2022. Retrieved December 1, 2022. "The Punisher". Eye for an Eye. (Vice) Bethesda Softworks LLC. Archived from the original on March 10, 2016. Retrieved September 14, 2016.
Cirrhosis is most commonly caused by medical conditions including alcohol-related liver disease, metabolic dysfunction–associated steatohepatitis (MASH – the progressive form of metabolic dysfunction–associated steatotic liver disease, previously called non-alcoholic fatty liver disease or NAFLD), heroin abuse, chronic hepatitis B, and chronic hepatitis C. Chronic heavy drinking can cause alcoholic liver disease. Liver damage has also been attributed to heroin usage over an extended period of time as well. MASH has several causes, including obesity, high blood pressure, abnormal levels of cholesterol, type 2 diabetes, and metabolic syndrome. Less common causes of cirrhosis include autoimmune hepatitis, primary biliary cholangitis, and primary sclerosing cholangitis that disrupts bile duct function, genetic disorders such as Wilson's disease and hereditary hemochromatosis, and chronic heart failure with liver congestion. Diagnosis is based on blood tests, medical imaging, and liver biopsy. Hepatitis B vaccine can prevent hepatitis B and the development of cirrhosis from it, but no vaccination against hepatitis C is available. No specific treatment for cirrhosis is known, but many of the underlying causes may be treated by medications that may slow or prevent worsening of the condition. Hepatitis B and C may be treatable with antiviral medications. Avoiding alcohol is recommended in all cases. Autoimmune hepatitis may be treated with steroid medications. Ursodiol may be useful if the disease is due to blockage of the bile duct.
Sources: en.wikipedia.org
=== Local === By delivering drugs almost directly to the site of action, the risk of systemic side effects is reduced. Skin absorption (dermal absorption), for example, is to directly deliver drug to the skin and, hopefully, to the systemic circulation. However, skin irritation may result, and for some forms such as creams or lotions, the dosage is difficult to control. Upon contact with the skin, the drug penetrates into the dead stratum corneum and can afterwards reach the viable epidermis, the dermis, and the blood vessels.
== Scope and definitions == There are numerous classes of natural products for which total synthesis is applied to. These include (but are not limited to): terpenes, alkaloids, polyketides. and polyethers. Total synthesis targets are sometimes referred to by their organismal origin such as plant, marine, and fungal. The term total synthesis is less frequently but still accurately applied to the synthesis of natural polypeptides and polynucleotides. The peptide hormones oxytocin and vasopressin were isolated and their total syntheses first reported in 1954. It is not uncommon for natural product targets to feature multiple structural components of several natural product classes.
=== U.S. prevention strategies === The CDC Clinical Practice Guideline for Prescribing Opioids for Pain was developed to help guide healthcare professionals toward safe and evidence-based use of opioid therapy. Large U.S. retail pharmacy chains are implementing protocols, guidelines, and initiatives to take back unused opioids, providing naloxone kits, and being vigilant about suspicious prescriptions. Insurance programs can help limit opioid use by setting quantity limits on prescriptions or requiring prior authorizations for certain medications. Many U.S. officials and government leaders have become involved in implementing preventive measures to decrease opioid usage in the U.S. Targeted education of medical providers and government officials can lead to provisions affecting opioid distribution by healthcare providers.
== Structure–activity relationship == Even though μ-opioid receptor (MOR) targeting drugs have been used for a long time, not much is known about the structure-activity relationship and the ligand-receptor interactions on the basis of well-defined biological effects on receptor activation or inhibition. Also, the distinction in the receptor-ligand interaction patterns of agonists and antagonists is not known for sure. One theory states that the morphinans biological activity could be determined by the size of the N-substituents. For example, antagonists usually have larger substituents, such as allyl- or cyclopropyl methyl at the morphinan nitrogen, while agonists generally contain a methyl group. On the other hand, agonist activity is also shown in ligands with larger groups at the morphinan nitrogen, and therefore this hypothesis is challenged.
== Description == Weight loss typically occurs when fewer calories are consumed than is expended by daily activities, physiological processes and physical exercise (known as a caloric deficit). If enough weight is lost due to a reduction in body fat, an individual may move from being overweight (25.0-29.9) or obese (30+) into a healthy weight range (18.5-24.9); however, continued weight loss beyond this point can lead to becoming underweight (< 18.5).
Sources: en.wikipedia.org
It is a synthetic five-amino-acid peptide that acts as a growth hormone secretagogue. Three of its residues are non-standard amino acids, and the chain ends in an amide rather than a free acid. The molecule is small enough that it can be characterised by routine peptide analytical techniques.
It has not received marketing approval as a medicine in the United States or the European Union. Supplied material is generally described and handled as a research chemical. Regulatory treatment varies by jurisdiction, and some countries restrict growth hormone secretagogues under sports or medicines legislation.
Earlier secretagogues were associated with broader hormonal responses, including measurable changes in cortisol and prolactin. Reports on this peptide describe a narrower profile in which growth hormone release is the most prominent effect. The observation is influential because it shapes how the compound is compared with other members of the same receptor family.
It is reported as the percentage of total peak area in a reversed-phase chromatogram. That number does not reflect water content, residual solvents, or counterions. The actual peptide content is therefore lower than the stated purity figure suggests.